Vipivotide Tetraxetan Lutetium
Lutetium vipivotide tetraxetan (177Lu-PSMA-617) is a radioligand therapy consisting of a PSMA-targeting small molecule ligand (vipivotide tetraxetan) labeled with the beta-emitting radioisotope lutetium-177, which selectively delivers therapeutic radiation to prostate-specific membrane antigen (PSMA)-expressing cancer cells. It is approved for treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), providing targeted radionuclide therapy that spares surrounding normal tissue. The therapeutic radiation induces DNA double-strand breaks in PSMA-expressing prostate cancer cells.
Therapeutic Areas
Pharmacokinetics (PK)
Pharmacodynamics (PD)
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
Lutetium vipivotide tetraxetan (177Lu-PSMA-617) is a radioligand therapy consisting of a PSMA-targeting small molecule ligand (vipivotide tetraxetan) labeled with the beta-emitting radioisotope lutetium-177, which selectively delivers therapeutic radiation to prostate-specific membrane antigen (PSMA)-expressing cancer cells. It is approved for treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), providing targeted radionuclide therapy that spares surrounding normal tissue. The therapeutic radiation induces DNA double-strand breaks in PSMA-expressing prostate cancer cells.
Yes, Vipivotide Tetraxetan Lutetium is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594730. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="vipivotide-tetraxetan-lutetium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/vipivotide-tetraxetan-lutetium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/vipivotide-tetraxetan-lutetium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/vipivotide-tetraxetan-lutetium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="vipivotide-tetraxetan-lutetium"></drugfyi-drug>